GB0324854D0 - App/ena antisense - Google Patents

App/ena antisense

Info

Publication number
GB0324854D0
GB0324854D0 GBGB0324854.9A GB0324854A GB0324854D0 GB 0324854 D0 GB0324854 D0 GB 0324854D0 GB 0324854 A GB0324854 A GB 0324854A GB 0324854 D0 GB0324854 D0 GB 0324854D0
Authority
GB
United Kingdom
Prior art keywords
app
ena
antisense
ena antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0324854.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXPRESSON BIOSYSTEMS Ltd
Sankyo Co Ltd
Original Assignee
EXPRESSON BIOSYSTEMS Ltd
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXPRESSON BIOSYSTEMS Ltd, Sankyo Co Ltd filed Critical EXPRESSON BIOSYSTEMS Ltd
Priority to GBGB0324854.9A priority Critical patent/GB0324854D0/en
Publication of GB0324854D0 publication Critical patent/GB0324854D0/en
Priority to PCT/GB2004/004483 priority patent/WO2005042777A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
GBGB0324854.9A 2003-10-24 2003-10-24 App/ena antisense Ceased GB0324854D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0324854.9A GB0324854D0 (en) 2003-10-24 2003-10-24 App/ena antisense
PCT/GB2004/004483 WO2005042777A2 (en) 2003-10-24 2004-10-22 App/ena antisense

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324854.9A GB0324854D0 (en) 2003-10-24 2003-10-24 App/ena antisense

Publications (1)

Publication Number Publication Date
GB0324854D0 true GB0324854D0 (en) 2003-11-26

Family

ID=29595770

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0324854.9A Ceased GB0324854D0 (en) 2003-10-24 2003-10-24 App/ena antisense

Country Status (2)

Country Link
GB (1) GB0324854D0 (en)
WO (1) WO2005042777A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113579A1 (en) 2008-03-11 2009-09-17 学校法人埼玉医科大学 Double-stranded nucleic acid molecule suitable for prevention or treatment of cancer, cancer cell proliferation inhibitor, and pharmaceutical preparation
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2013019954A1 (en) 2011-08-04 2013-02-07 Amgen Inc. Method for treating bone gap defects
JP6129844B2 (en) 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド Multimeric oligonucleotide compounds
CA2858974A1 (en) 2011-12-28 2013-07-04 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
DK2850186T3 (en) 2012-05-16 2019-04-08 Translate Bio Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
KR102028784B1 (en) 2012-05-16 2019-10-04 트랜슬레이트 바이오 인코포레이티드 Compositions and methods for modulating gene expression
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
CR20210393A (en) * 2018-12-19 2021-10-27 Alnylam Pharmaceuticals Inc AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP3918073A4 (en) * 2019-01-29 2023-11-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
CN1273478C (en) * 1999-02-12 2006-09-06 三共株式会社 Novel nucleosides and oligonucleotide analogues
US6310048B1 (en) * 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
GB0105787D0 (en) * 2001-03-08 2001-04-25 Expresson Biosystems Ltd Complex element micro-array and methods of use
US20030232435A1 (en) * 2002-06-14 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of amyloid beta protein precursor expression

Also Published As

Publication number Publication date
WO2005042777A2 (en) 2005-05-12
WO2005042777A3 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
GB0324854D0 (en) App/ena antisense
DE602004013036D1 (en) Us
GB0315259D0 (en) Use
DE112004002769D2 (en) Schienengeführtes transportsystem
GB0302741D0 (en) Use
IL155549A0 (en) Timer
DE10394343D2 (en) Berührungslose biometrische erkennung
GB0314557D0 (en) Improved reduction calculations
GB0313913D0 (en) New use
GB0324592D0 (en) Level exstention
GB2392820B (en) G-string
AU2003275143A8 (en) Triplex hairpin ribozyme
GB0322735D0 (en) New level
GB0327619D0 (en) New use
GB0316757D0 (en) Use
GB0321391D0 (en) Flexi-facial plus
GB0722959D0 (en) Stable intergrands
PL361719A1 (en) Tampon
AU2834P (en) Baltinblus Gaura lindheimeri
AU2833P (en) Baltinrose Gaura lindheimeri
GB0315866D0 (en) New use
GB0303391D0 (en) Nanotopography
GB0311020D0 (en) Dressing
GB0300295D0 (en) Use
GB0310755D0 (en) Use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)